Nivolumab therapy for a pediatric-onset primary intracranial melanoma

Pediatr Int. 2022 Jan;64(1):e14956. doi: 10.1111/ped.14956.

Authors

Utako Oba¹, Yuhki Koga¹, Nobuhiro Hata², Yoshinao Oda³, Shouichi Ohga¹

Affiliations

¹ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
³ Department of Anatomic Pathology, Graduate of School of Medical Science, Kyushu University, Fukuoka, Japan.

PMID: 35484924
DOI: 10.1111/ped.14956

No abstract available

Keywords: chemotherapy; child; immune checkpoint inhibitor; intracranial melanoma; nivolumab.

MeSH terms

Brain Neoplasms* / drug therapy
Child
Humans
Melanoma* / drug therapy
Nivolumab / therapeutic use

Substances

Nivolumab